Role of EGFR and FASN in breast cancer progression.

IF 3.6 3区生物学 Q3 CELL BIOLOGY

Journal of Cell Communication and Signaling Pub Date : 2023-12-01 Epub Date: 2023-07-25 DOI:10.1007/s12079-023-00771-w

Suchi Chaturvedi, Mainak Biswas, Sushabhan Sadhukhan, Avinash Sonawane

{"title":"Role of EGFR and FASN in breast cancer progression.","authors":"Suchi Chaturvedi, Mainak Biswas, Sushabhan Sadhukhan, Avinash Sonawane","doi":"10.1007/s12079-023-00771-w","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer (BC) emerged as one of the life-threatening diseases among females. Despite notable improvements made in cancer detection and treatment worldwide, according to GLOBACAN 2020, BC is the fifth leading cancer, with an estimated 1 in 6 cancer deaths, in a majority of countries. However, the exact cause that leads to BC progression still needs to be determined. Here, we reviewed the role of two novel biomarkers responsible for 50-70% of BC progression. The first one is epidermal growth factor receptor (EGFR) which belongs to the ErbB tyrosine kinases family, signalling pathways associated with it play a significant role in regulating cell proliferation and division. Another one is fatty acid synthase (FASN), a key enzyme responsible for the de novo lipid synthesis required for cancer cell development. This review presents a rationale for the EGFR-mediated pathways, their interaction with FASN, communion of these two biomarkers with BC, and improvements to overcome drug resistance caused by them.</p>","PeriodicalId":15226,"journal":{"name":"Journal of Cell Communication and Signaling","volume":" ","pages":"1249-1282"},"PeriodicalIF":3.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713975/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cell Communication and Signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s12079-023-00771-w","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Breast cancer (BC) emerged as one of the life-threatening diseases among females. Despite notable improvements made in cancer detection and treatment worldwide, according to GLOBACAN 2020, BC is the fifth leading cancer, with an estimated 1 in 6 cancer deaths, in a majority of countries. However, the exact cause that leads to BC progression still needs to be determined. Here, we reviewed the role of two novel biomarkers responsible for 50-70% of BC progression. The first one is epidermal growth factor receptor (EGFR) which belongs to the ErbB tyrosine kinases family, signalling pathways associated with it play a significant role in regulating cell proliferation and division. Another one is fatty acid synthase (FASN), a key enzyme responsible for the de novo lipid synthesis required for cancer cell development. This review presents a rationale for the EGFR-mediated pathways, their interaction with FASN, communion of these two biomarkers with BC, and improvements to overcome drug resistance caused by them.

Abstract Image

查看原文本刊更多论文

表皮生长因子受体和 FASN 在乳腺癌进展中的作用。

乳腺癌（BC）是威胁女性生命的疾病之一。尽管全球在癌症检测和治疗方面取得了显著进步，但根据 GLOBACAN 2020 的数据，在大多数国家，乳腺癌仍是第五大主要癌症，估计每 6 人中就有 1 人死于乳腺癌。然而，导致 BC 进展的确切原因仍有待确定。在此，我们回顾了两种新型生物标志物的作用，这两种生物标志物导致了50-70%的BC进展。第一个是表皮生长因子受体（EGFR），它属于ErbB酪氨酸激酶家族，与之相关的信号通路在调节细胞增殖和分裂方面发挥着重要作用。另一种是脂肪酸合成酶（FASN），它是癌细胞发育所需的一种负责新脂质合成的关键酶。这篇综述介绍了表皮生长因子受体介导的途径、它们与 FASN 的相互作用、这两种生物标志物与 BC 的关系，以及克服由它们引起的耐药性的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cell Communication and Signaling CELL BIOLOGY-

CiteScore

6.40

自引率

4.90%

发文量

期刊介绍： The Journal of Cell Communication and Signaling provides a forum for fundamental and translational research. In particular, it publishes papers discussing intercellular and intracellular signaling pathways that are particularly important to understand how cells interact with each other and with the surrounding environment, and how cellular behavior contributes to pathological states. JCCS encourages the submission of research manuscripts, timely reviews and short commentaries discussing recent publications, key developments and controversies. Research manuscripts can be published under two different sections : In the Pathology and Translational Research Section (Section Editor Andrew Leask) , manuscripts report original research dealing with celllular aspects of normal and pathological signaling and communication, with a particular interest in translational research. In the Molecular Signaling Section (Section Editor Satoshi Kubota) manuscripts report original signaling research performed at molecular levels with a particular interest in the functions of intracellular and membrane components involved in cell signaling.